Pierre Côte, PhD, MBA’s Post

Today, Nature Reviews Drug Discovery published our research titled: “Comprehensive measurement of biopharmaceutical R&D investment." In this paper, we introduce a transparent and replicable measure to capture the entire innovative private sector R&D ecosystem (spanning public and private firms across the development and commercial stages) which shows that the scale of pharmaceutical research is much larger than commonly reported. Key findings: - Scale of investment far surpasses previous estimates: $276 billion of pharmaceutical R&D investment across 4,191 global companies in 2021. - The U.S. leads the way in researching medicines: 48% of global biopharma R&D companies are based in the U.S., providing 55% of worldwide R&D and 65% of all development-stage funding. U.S. firms also reinvest the largest share of their revenue back into research. Researchers can now make informed, evidence-based decisions, basing models and estimates on the novel methodology that captures all R&D contributions within the interconnected pharma ecosystem. Thank you to my co-authors: Amitabh Chandra, Ulrich Neumann, Noam Kirson, Michael Daly, Henry Mirsberger, and Samuel Spare. Please read the full analysis here: https://lnkd.in/enEksftr #Innovation #Investment #Pharma  #PolicyResearch 

📣 Calling anyone in my network who works in the strategic partnerships or alliance management space in R&D Pharma, Biotech or Healthcare 💪 We're looking for folks to take part in our short survey to share their perspectives below (you'll receive the report afterwards). Let me know if you ever want to chat about this topic at such an exciting time for the industry!

What are the pharmaceuticals and life sciences trends and perspectives on R&D strategic partnerships? A strategic partnership in R&D refers to a mutually beneficial collaboration or alliance between two or more organisations, such as pharmaceutical companies, academic institutions, or biotech firms, with the aim of jointly pursuing R&D activities to achieve shared research outcomes. We're working with clients to build stronger strategic partnerships in R&D to leverage their strengths, share risks, and unlock innovation. Complete our survey to share your thoughts and contribute to the conversation ahead of the results being released later this summer: https://ow.ly/1JJC50RQA4t Kate Moss (nee Watkins) Laveshni Reddy Joshua Elliott Chris Maxted Samantha Sierwald #biotech #biopharma #pharma #lifesciences #pharmaceuticals #biotechnology

Sharing with my network in case there is anyone who would like to take part in our survey on trends and perspectives on R&D strategic partnerships. If you do take part, you will receive the full insights report when it is ready later this summer. #pharmaceuticals #biotech #strategicpartnerships #pharma #lifesciences

NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals Shares Biopharma Ontologies with Open Applications Group (OAGi) Learn more & get our take 👇 https://lnkd.in/g3vbH2YZ "These biopharma-specific ontologies will improve interoperability and optimize productivity by allowing data engineers to access, analyze, and share data about their manufacturing processes." — Roger Hart, Senior Fellow and Big Data Project Lead at NIIMBL "It is with great excitement that NIIMBL has contributed this ontology and is interested in broadening its applicability to other manufacturing industry sectors." — Serm (Boonserm) Kulvatunyou, Researcher at National Institute of Standards and Technology (NIST) and Co-founder at IOF "The NIIMBL-contributed ontologies are the first step in a journey to radically improve interoperability in the biopharmaceutical manufacturing industry." — Jim Wilson, CEO at OAGi #biopharma #manufacturing #SoMFNews

Interesting read on R&D, biotech, Pharma, policy and drug pricing. Carving out a vibrant and successful biomedical ecosystem. #policy #research #drug https://lnkd.in/gwuGiDmy

In the face of rising R&D costs and growing pricing pressures from payers, the #pharma and #biotech sectors continue to transform to adapt to an evolving landscape. Here, we highlight new pharma and biotech manufacturing facilities and expansions announced worldwide for 2024: https://lnkd.in/eRB-zKjF #manufacturing #PharmaceuticalManufacturing #PharmaManufacturing

📈 Dig into #drugdevelopment trends with this on-demand webinar! An expert panel discusses key findings from a survey of 150 leaders at #biotech and #pharmaceutical organizations around the world. Listen in to explore the implications of these trends for #drugdevelopers, and gain insights into R&D strategies and new technologies.

Director Christopher Gallo will speak during Module 1: "Identifying and Comprehending Pre-Commercialization Concerns Relative to Small Molecules and Biologics" at ACI’s 4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA on October 8, 2024. https://lnkd.in/eS3_-QU5 In this session, the speakers will cover: 🔹 The current pre-commercialization landscape for pharmaceuticals, biotech, and biopharma companies 🔹 Patent and regulatory challenges during product development 🔹 Techniques for assessing product value and potential competition 🔹 Considerations in light of healthcare reform, including how follow-on biologics and biosimilars have changed the commercial landscape and the role of CMS in the approval process #HatchWaxman #BPCIA #Pharmaceuticals #Biotechnology

In today’s competitive environment, research reveals that one third of all drug launches fall short of biopharma companies’ expectations. But this doesn’t have to be the case.   In the first instalment of our new four-part video series, Ryoko Yamasaki, Principal, Veeva Business Consulting Asia shares how biopharmas can understand the market landscape, set a strong foundation to develop navigate the complex biopharmaceutical environment, especially during crucial periods like drug launches and set themselves up for success.   Stay tuned for upcoming episodes, where other Veeva experts including DU LIN, Sushant Aggarwal and Daniel Bacon touch on other critical aspects of the product launch process, to achieve meaningful impact and greater success. Read our white paper for more insights: https://lnkd.in/gt6UgsYc